Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 16, 2021.
Glucocorticoid withdrawal over a prolonged period of time did not increase clinical flares or damage for patients with inactive systemic lupus erythematosus.
Given the low prevalence of anti-Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) in women with rheumatoid arthritis who would like to conceive, intensive echocardiographic screening may not be necessary.
In this observational cross-sectional study, investigators created a survey designed to understand the management and follow-up of patients during the COVID-19 pandemic in Latin American countries.
Research indicates that patients with autoimmune rheumatic diseases (AIRD) did not differ from the general population in terms of protective antibody responses against COVID-19.
Surprisingly, patients with rheumatoid arthritis and erectile dysfunction had a significantly decreased rate of myocardial infarction, heart failure, and death when compared with patients with rheumatoid arthritis alone.
“This analysis provides information on when clinically meaningful improvements in pain may be expected in patients with psoriatic arthritis receiving tofacitinib or adalimumab, and how baseline pain severity may impact response to tofacitinib, which is of value in clinical practice,” stated investigators.
On the latest episode of Overdrive, we sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 9, 2021.
Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.
Claire Daien, MD, discusses the safety and efficacy of ABX464, the primary and secondary endpoints, and what differentiates the medication from other rheumatoid arthritis therapies.
Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 2, 2021.
Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2021.
In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.
An SMS-based, interactive, educational video greatly increased information related to COVID-19 vaccines, confidence in vaccine safety, and an inclination to receive the vaccine.
The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.
Upadacitinib (UPA) effectively treated patients with psoriatic arthritis (PsA) and axial involvement, a group that is historically more likely to have higher disease burden and more quality-of-life impairments than patients without axial involvement.
Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 18, 2021.
Rheumatology Network sat down with Mehret Birru Talabi, MD, PhD, to discuss the recent study published in ACR Open Rheumatology entitled, “Tough choices: Exploring medication decision-making during pregnancy and lactation among women with inflammatory arthritis.”
Jeffrey Stark, MD, discusses the statement UCB issued endorsing the creation of a new sub-category (M.45A) for non-radiographical axial spondyloarthritis (nr-axSpA).
In today's episode, we sat down with Daniel Hernandez, MD, and Shilpa Venkatachalam, PhD, MPH, of CreakyJoints, to highlight health disparities in marginalized communities and introduce their exciting new venture, CreakyJoints Espanol.
In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 11, 2021.
Liana Fraenkel, MD, MPH, discusses the recent updates to the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, for which she served as part of the Core Leadership Team.
Risankizumab showed significantly greater improvements in symptoms of psoriatic arthritis when compared with a placebo and was well tolerated in patients who were intolerant to biologics and conventional synthetic disease-modifying antirheumatic drugs.